Coverage Policies, Benefit Routes, and Public Financial Terms for Prescription Digital Therapeutics in the United States: A Cross-Sectional Health Policy and Market Access Study

BackgroundPrescription digital therapeutics (PDTs) may be addressed through clinical policies, pharmacy benefits, purchaser-selected catalogs, or professional-care payment rules.A single covered/not-covered designation can obscure differences in scope, distribution, and financial responsibility.This study examined how these distinctions appear in a public-source corpus. MethodsAn exploratory cross-sectional health policy and market access study used an October 4, 2026 snapshot.Twenty-two regulatory-anchored therapeutic program families were classified as general-purpose-device programs or software-primary systems.Adaptive public-source searches assembled policy, benefit, program, and financial records.Operational product-scope statements were separated from general frameworks, historical documents, and manufacturer-reported access.Descriptive counts and sensitivity analyses were generated from source-linked data; national coverage prevalence and covered lives were not estimated. ResultsThe dataset contained 35 operational source records.Twelve current-posted position documents from 10 publishing families supported 57 product-scope mappings across 21 of the 22 programs: 54 restrictive, two supporting conditional clinical eligibility, and one class-based mapping with unresolved delivery-setting applicability.Restrictive mappings comprised 45 medical/clinical-policy and nine pharmacy records; 48 were named and six class-derived.Anthem's product-specific guideline contributed 15 restrictive mappings and addressed both listed applications and associated management services.Conditional clinical eligibility involved Luminopia (Luminopia, Inc., Cambridge, MA, USA) and CureSight (NovaSight Ltd., Airport City, Israel); the intravaginal biofeedback class mapped to leva (Axena Health, Inc., Newton, MA, USA) remained setting-uncertain.Deduplication across repeated family-product-route positions retained 53 mappings.The general-purpose-device-only analysis retained 30 restrictive mappings and excluded both conditionaleligibility mappings and the setting-uncertain mapping.Ten additional pathway records distinguished exception guidance, Medicare professional-care payment, optional digital catalogs, non-drug list architecture, and manufacturer reports.Fifteen financial observations were heterogeneous: a currentdisplayed $99 EndeavorRx (Akili Interactive Labs, Inc., Boston, MA, USA) prescription price, an expired $99 Rejoyn (Otsuka America Pharmaceutical, Inc., Rockville, MD, USA) offer, a $25 leva evaluation fee, and a $2,100 economic-model input were not interchangeable. ConclusionsFDA authorization and billing codes did not establish favorable medical-necessity decisions in this corpus.Product-specific restrictions, exemplified by Anthem's October 2026 guideline, coexisted with conditional pathways elsewhere.Clinical access assessment should verify the governing policy, plan adoption, benefit route, and patient cost before treatment.The broader product definition retained clinical-eligibility pathways and an uncertain class mapping excluded by the general-purpose-device-only analysis.These findings characterize selected documents, not national coverage prevalence or realized patient access.